Home › Funds › Stonepine Capital Management, LLC › ZNTL
Stonepine Capital Management, LLC position in ZNTL
ZENTALIS PHARMACEUTICALS INC · Health Care
Stonepine Capital Management, LLC reported holding 254,759 shares of ZNTL (ZENTALIS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$706K, representing 0.54% of its reported portfolio and ranking #38 among its reported holdings. Stonepine Capital Management, LLC has disclosed ZNTL holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Stonepine Capital Management, LLC's ZNTL position evolved
Stonepine Capital Management, LLC first disclosed a stake in ZNTL in Q1 2025 at 60,000 shares (US$95K). The position peaked in Q2 2026 at 161,583 shares, worth US$784K. Across 7 filings, Stonepine Capital Management, LLC increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 254,759 shares valued at US$706K — an increase of 93,176 shares quarter over quarter.. Notable position changes include a 82% increase in Q2 2025 (shares rose 30% over the following quarter), a 316% increase in Q3 2025 (shares fell 11% over the following quarter), a 58% increase in Q3 2026 (shares fell 39% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 60.00K | $95.40K | New |
| Q2 2025 | 109.01K | $126.45K | Add |
| Q3 2025 | 453.80K | $685.24K | Add |
| Q4 2025 | 463.70K | $626.00K | Add |
| Q1 2026 | 269.10K | $629.69K | Reduce |
| Q2 2026 | 161.58K | $783.68K | Reduce |
| Q3 2026 | 254.76K | $705.68K | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZNTL and 13F data
ZNTL (ZENTALIS PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in ZNTL — the largest reported positions include 5AM Venture Management, LLC (US$19.1M), Opaleye Management Inc. (US$6.9M), Patient Square Capital LP (US$5.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZNTL
- 5AM Venture Management, LLC 3.95M sh · $19.15M · Q2 2026
- Opaleye Management Inc. 1.41M sh · $6.85M · Q2 2026
- Patient Square Capital LP 2.01M sh · $5.56M · Q3 2026
- Ishara Investments LP 1.02M sh · $4.97M · Q2 2026
- Decheng Capital LLC 1.32M sh · $3.67M · Q3 2026
- PFIZER INC 953.83K sh · $2.58M · Q3 2026
- Squadron Capital Management LLC 426.00K sh · $2.07M · Q2 2026
More on Stonepine Capital Management, LLC
FAQ
How long has Stonepine Capital Management, LLC held ZNTL?
Stonepine Capital Management, LLC has disclosed ZNTL holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is Stonepine Capital Management, LLC's current position in ZNTL?
As of Q3 2026, Stonepine Capital Management, LLC holds 254.76K shares of ZNTL (ZENTALIS PHARMACEUTICALS INC), valued at $705.68K, representing 0.54% of its reported portfolio and ranking #38.
Has Stonepine Capital Management, LLC been buying or selling ZNTL?
In the latest 13F filing (Q3 2026), Stonepine Capital Management, LLC increased its position in ZNTL. The position peaked in Q2 2026 at 161.58K shares.
Which other funds hold ZNTL?
Other major institutional holders of ZNTL include 5AM Venture Management, LLC, Opaleye Management Inc., Patient Square Capital LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.